A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

(2021) Jan Philipp Bewersdorf et al.   Cancers

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma

(2020) Alessia Villani et al.   Dermatology and Therapy

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms

(2020) Laura Palomo et al.   BLOOD

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

(2020) Mikkael A. Sekeres et al.   Blood Advances

Determination of fitness and therapeutic options in older patients with acute myeloid leukemia

(2020) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis

(2019) Alison Booth et al.   JOURNAL OF MEDICAL INTERNET RESEARCH

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development

(2019) Hitoshi Kiyoi et al.   CANCER SCIENCE

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

(2018) Michael R. Savona et al.   CLINICAL CANCER RESEARCH

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

(2018) Dale Bixby et al.   BRITISH JOURNAL OF HAEMATOLOGY

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

(2018) Jorge E. Cortes et al.   LEUKEMIA

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

(2017) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia

(2015) Yiting Lim et al.   Science Translational Medicine

How we treat higher-risk myelodysplastic syndromes

(2013) M. A. Sekeres et al.   BLOOD

Outcome of older patients with acute myeloid leukemia

(2013) Mya S. Thein et al.   CANCER

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

(2011) Christoph Röllig et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD